肝细胞癌内在CCRK抑制减少髓源性抑制细胞免疫抑制并增强免疫检查点阻断疗效
该研究探讨肝细胞癌内在细胞周期相关激酶(CCRK)对髓源性抑制细胞(MDSC)免疫抑制的调控作用。患者来源MDSC抑制自体CD8+T细胞增殖,CCRK与MDSC标志物共表达与较差生存率正相关;机制上CCRK经EZH2/NF-κB/IL-6轴促进PMN-MDSC积聚,抑制肿瘤Ccrk可上调PD-L1并增强PD-L1阻断疗效。
要点
- 肝细胞癌浸润CD11b+CD33+HLA-DR- MDSC抑制自体CD8+T细胞增殖。
- CCRK与MDSC标志物(CD11b/CD33)共表达与较差生存率正相关。
- 抑制肿瘤Ccrk上调PD-L1表达、增加瘤内CD8+T细胞并增强PD-L1阻断疗效。
核心结论
- 研究阐明肝细胞癌内在CCRK信号通路的免疫抑制机制,并提示抑制该过表达激酶可能增强肝细胞癌免疫治疗。
研究设计与样本
- 采用流式细胞术、表达分析和共培养体系检测肝细胞癌患者来源MDSC的免疫抑制及其与CCRK的关系。
- 在肝特异性CCRK可诱导转基因(TG)小鼠和Hepa1-6原位肝细胞癌模型中开展机制研究,使用CRISPR/Cas9介导Ccrk敲除及肝靶向纳米颗粒捕获白细胞介素6。
- 在单用或联用抗程序性死亡配体1(PD-L1)治疗中评估致瘤性和免疫表型。
主要发现
- 肝细胞癌患者肿瘤浸润CD11b+CD33+HLA-DR- MDSC可有效抑制自体CD8+T细胞增殖。
- CCRK与MDSC标志物(CD11b/CD33)一致性过表达与较差生存率正相关。
- 肝细胞CCRK通过上调IL-6刺激人外周血单个核细胞扩增免疫抑制性CD11b+CD33+HLA-DR- MDSC。
- 机制上CCRK经增强子同源物2(EZH2)激活核因子-κB(NF-κB),并促进NF-κB-EZH2共结合至IL-6启动子。
- TG小鼠肝脏CCRK诱导激活EZH2/NF-κB/IL-6级联,导致具有强T细胞抑制活性的多形核(PMN)MDSC积聚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Myeloid-derived suppressor cells (MDSCs) contribute to tumour immunosuppressive microenvironment and immune-checkpoint blockade resistance. Emerging evidence highlights the pivotal functions of cyclin-dependent kinases (CDKs) in tumour immunity. Here we elucidated the role of tumour-intrinsic CDK20, or cell cycle-related kinase (CCRK) on immunosuppression in hepatocellular carcinoma (HCC). DESIGN: Immunosuppression of MDSCs derived from patients with HCC and relationship with CCRK were determined by flow cytometry, expression analyses and co-culture systems. Mechanistic studies were also conducted in liver-specific CCRK-inducible transgenic (TG) mice and Hepa1-6 orthotopic HCC models using CRISPR/Cas9-mediated Ccrk depletion and liver-targeted nanoparticles for interleukin (IL) 6 trapping. Tumorigenicity and immunophenotype were assessed on single or combined antiprogrammed death-1-ligand 1 (PD-L1) therapy. RESULTS: Tumour-infiltrating CD11b+CD33+HLA-DR- MDSCs from patients with HCC potently inhibited autologous CD8+T cell proliferation. Concordant overexpression of CCRK and MDSC markers (CD11b/CD33) positively correlated with poorer survival rates. Hepatocellular CCRK stimulated immunosuppressive CD11b+CD33+HLA-DR- MDSC expansion from human peripheral blood mononuclear cells through upregulating IL-6. Mechanistically, CCRK activated nuclear factor-κB (NF-κB) via enhancer of zeste homolog 2 (EZH2) and facilitated NF-κB-EZH2 co-binding to IL-6 promoter. Hepatic CCRK induction in TG mice activated the EZH2/NF-κB/IL-6 cascade, leading to accumulation of polymorphonuclear (PMN) MDSCs with potent T cell suppressive activity. In contrast, inhibiting tumorous Ccrk or hepatic IL-6 increased interferon γ+tumour necrosis factor-α+CD8+ T cell infiltration and impaired tumorigenicity, which was rescued by restoring PMN-MDSCs. Notably, tumorous Ccrk depletion upregulated PD-L1 expression and increased intratumorous CD8+ T cells, thus enhancing PD-L1 blockade efficacy to eradicate HCC. CONCLUSION: Our results delineate an immunosuppressive mechanism of the hepatoma-intrinsic CCRK signalling and highlight an overexpressed kinase target whose inhibition might empower HCC immunotherapy.
引用
- Zhou J, Liu M, Sun H, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2017. PMID: 28939663. doi:10.1136/gutjnl-2017-314032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。